Single-dose randomized, open-label, 2-way crossover bioequivalence study of clopidogrel 75 mg tablet in healthy volunteers under fasting conditions

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 3, 2009, Pages 187-194

  Filipe, A ^a   Almeida, S ^a,b   Franco Spinola, A C ^a   Neves, R ^a   Tanguay, M ^c   Jimenez C ^d   Shink, E ^c  

^a Tecnimede Group   (Portugal)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Anapharm Canada   (Canada)

^d Anapharm Europe SL   (Spain)

Author keywords

AUC; Bioequivalence; Cmax; CAS 120202 66 6; Clopidogrel pharmacokinetics

Indexed keywords

CARBOXYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TICLOPIDINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; FILM COATING; HUMAN; HUMAN EXPERIMENT; INJECTION SITE PAIN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE DRUG DOSE; TABLET FORMULATION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; COMPARATIVE STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MIDDLE AGED; PHARMACOKINETICS; TABLET;

ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; FASTING; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; TABLETS; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY; TICLOPIDINE;

EID: 65549122187     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47187     Document Type: Article

References (11)

1. Angiolillo DJ, Guzman LA, Bass TA. Current antiplatelet therapies: benefits and limitations. Am Heart J. 2008; 156: S3-S9.
2. Beckerath N von, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A. Absorption, metabolization, and antiplatelet effects of 300, 600, and 900 mg loading doses of clopidogrel, results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005; 112: 2946-2950.
3. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98. July 2001; p. 1-18.
4. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P4503A and is inhibited by atorvastatin. Drug Metab Dispos. 2003; 31: 53-59.
5. EMEA. Prescribing information of the reference product (Plavix). Revised March. 2008.
6. Good Clinical Practice Consolidated Guideline. International Conference on Harmonisation, E6. 2002; p. 1-59.
7. Lainesse A, Ozalp Y, Wong H, Alpan RS. Bioequivalence study of clopidogrel bisulfate film-coated tablets. Arzneimittelforschung. 2004; 54: 600-604.
8. McEwen J, Strauch G, Perles P, Pritchard G, Moreland TE, Necciari J et al. Clopidogrel bioavailability: absence of influence of food or antacids. Semin Thromb Hemost. 1999; 25 (Suppl. 2): 47-50.
9. Nirogi RV, Kandikere VN, Mudigonda K. Food substantially enhanced the bioavailability of clopidogrel in healthy subjects. Arzneimittelforschung. 2006; 56: 735-739.
10. Savi P, Combalbert J, Gaich C, Rouchon M-C, Maffrand J-P, Berger Y et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost. 1994; 72: 313-317.
11. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand J-P et al. Identification and biological activity of the active metabolite of clopidogrel 2000; Thromb Haemost. 84: 891-896.